Close menu

August 24th, 2022 | 13:24 CEST

BYD, Meta Materials, Pfizer - Full pipeline

  • metamaterials
  • Electromobility
  • Biotechnology
Photo credits:

Uncertainty returns after the rises of recent weeks. In addition to equities, other asset classes such as precious metals and cryptocurrencies are also falling and marking a multi-week low. Besides the uncertain geopolitical situation, the culprit is mainly the fear of a global recession bundled with rampant inflation. It is challenging to currently filter out the right stocks from this overall negative environment. Nevertheless, many companies are shining with full order books and innovations and should benefit in the long term in the event of a turnaround.

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: BYD CO. LTD H YC 1 | CNE100000296 , Meta Materials Inc. | US59134N1046 , PFIZER INC. DL-_05 | US7170811035

Table of contents:

    BYD - Solid as a rock

    While the US technology index Nasdaq has lost up to 34% at its low point since the beginning of the year and most electric car manufacturers also suffered heavy losses, Shenzhen-based BYD shone with relative strength and a clear outperformance. The "Build Your Dream" share has gained 15% since January 1, 2022. The reasons for the outperformance are manifold. On the one hand, the Company was able to knock the top dog Tesla off its throne in its home market and clearly distance itself from it. A total of 641,350 units were sold in the first half of the year, an increase of 314.90% over the same period last year.

    In order to expand its market position, BYD is focusing entirely on producing pure electric and plug-in hybrid vehicles and has stopped the production of gasoline vehicles. In addition, the battery business is growing, which made BYD one of the world's top 3 battery producers. According to experts, the reason for the strong development is that the blade technology is considered one of the safest and most reliable in the industry. BYD also wants to supply the battery to other car manufacturers; Tesla, for example, has long been considered a potential customer.

    In the field of electric cars, the Company plans to expand into the European countries Germany, Sweden, Norway and Denmark. HANs, Tangs and the Atto 3 are also expected to roll on the roads in Israel, Thailand and Cambodia in the future. From a chart perspective, the share has taken a short break recently and is trading at USD 35.12. The 200-day line is currently at USD 33.60. Despite excellent long-term fundamental prospects, a setback to the upward trend formed since May 2021 is certainly possible.

    Meta Materials - Commercialization making progress

    After the turnaround in the monetary policy and the at least temporary abandonment of money printing, growth stocks, in particular, have slumped significantly since the beginning of the year. In the process, one of last year's stock market stars came under heavy fire, although growth and the expansion of technology continue to be highly innovative and promising. Meta Materials, which was named "Lux Research Innovator of the Year 2021", has lost a staggering 96% since its high in June last year. The stock market value is currently only around USD 290 million.

    It is precisely because of this enormous loss that it is worth taking a closer look at the Nasdaq company. The developer of high-performance functional materials and nanocomposites is on the verge of redefining the future of coating materials. Metamaterials is the magic word in which the market leader from Canada has secured 410 active patent documents, including 251 issued patents and 159 pending patent applications, and has extended its lead over competitors. Meta Materials' patent portfolio amounts to 98 patent families, of which 57 contain at least one granted patent.

    With research into novel high-performance materials, it will be possible in the future to redirect light, sound, heat or radio waves through the development of unique nanotechnology. The innovative technology can be rolled out globally and across industries, such as 5G communications, health and wellness, aerospace, automotive and renewable energy.

    Second quarter figures showed a huge revenue increase of 432% to USD 3.3 million. In contrast, a loss of USD 21 million was incurred due to development costs, which is the rule rather than the exception at this stage of the Company's development. Meta Materials was also able to strengthen its personnel once again. Jack Harding, a chip industry veteran, was appointed Chairman of the Board of Directors. As a former director at RF Micro Devices, he was involved in the merger with TriQuint Semiconductor to form Qorvo, which today has a leading position in high-energy RF electronics and a market capitalization of USD 11 billion. He was also a board member of chip giant Advanced Micro Devices as the Company began its transformation into an industry leader.

    Pfizer - Ready for the next wave

    The US pharmaceutical giant Pfizer is closer to the formed uptrend that started since the Corona low in March 2020. The Dow Jones Group distributes the vaccine against COVID-19, Comirnaty, with the Mainz biotech company BioNTech. With a current quotation at just under USD 49, the Americans are in danger of breaking through the striking support at USD 47.57. That would trigger a new sell signal to the next stop at USD 43.08.

    Tailwinds are coming to vaccine producers ahead of the upcoming fall and the threat of the next strong wave of infections. With partner BioNTech, Pfizer now applied to the US Food and Drug Administration for emergency approval of a Corona vaccine adapted to the currently circulating Omicron variants BA.4 and BA.5. In addition, according to a press release, an application will also be submitted to the European Medicines Agency (EMA). In the event of positive approval results, the companies expect to start deliveries as early as September. A critical aspect is the fact that there are still no clinical studies for the adapted version.

    Stock market losses have increased significantly recently due to fears of recession. Growth stocks such as Meta Materials have lost disproportionately, although enormous potential lies dormant here. BYD is still in correction mode, and things could get uncomfortable for Pfizer after the break in the upward trend.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author

    Related comments:

    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.


    Commented by Juliane Zielonka on November 30th, 2023 | 07:00 CET

    Growth Industries in Focus: Investors see potential in Defense Metals, BASF and Volkswagen shares

    • Mining
    • Tungsten
    • RareEarths
    • Electromobility

    Investors are looking for opportunities in growing markets. Looking at industries currently requiring rare earths - such as energy, defense, electromobility, and many more - leads to the mining sector. Someone has to supply the valuable raw materials so these industries can continue growing. Defense Metals' Wicheeda project in Canada shows promising results, particularly the increase to 6.4 million tons with a TREO content of 2.86%. BASF secures EUR 124.3 million in government funding for a green hydrogen plant in Ludwigshafen, planned in collaboration with Siemens Energy. Volkswagen is facing challenges, emphasized by VW board member Thomas Schäfer, who announced tough cuts to maintain competitiveness without closing plants. Volkswagen will have to respond to change with a more agile approach, especially as China advances in electromobility.


    Commented by Armin Schulz on November 29th, 2023 | 06:30 CET

    MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?

    • Biotechnology
    • Pharma

    2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.